Yahoo Finance

Many brokerage firms that serve retail and institutional clients maintain data to measure investment sentiment. This can be very valuable when evaluating how the small investor, or even the corporate giants, are feeling about the stock market -- and, more importantly, what are they doing with their funds. Charles Schwab is one of those firms, with its Schwab Trading Activity Index, or STAX. STAX is a proprietary, behavior-based index designed to indicate the sentiment of retail investors and has been incorporating data since January 2019. In April, STAX fell to 41.2, down 15% from 48.4 in March and the lowest headline reading since April 2023. The STAX fell every week of the April period, though the first week saw the heaviest selling as STAX fell 11%, the biggest weekly drop since the first week of April 2023. The third week of the four saw only mild net-selling, but selling accelerated again in the final week (ended April 25). On a monthly basis, April's overall STAX plunge of 14.9% was the deepest drop since March 2020, the first full month of the COVID-19 pandemic. This is just another example of what we have been talking about for weeks, namely the similarity between 2025's correction and the pandemic correction. The current STAX reading is closing in on the low level of 37.2 at the end of 2022, right after that bear market bottomed. During the 2023/2024 market advance, the index never got out of neutral territory, peaking at 55. (Mark Arbeter, CMT)

Coloplast is a leading global competitor in ostomy management and continence care. The firm designs, manufactures, and markets ostomy care systems, disposable containment devices, paste, powder, seals, and intermittent catheters for continence care. Coloplast also maintains a tertiary presence in the urology and woundcare markets, where it manufactures and markets penile implants, slings for incontinence and prolapse, and wound dressings. The company derives more than 60% of sales from Europe, 24% from other developed countries, and 17% from the rest of the world.

WEST PHARMACEUTICAL SERVICES has an Investment Rating of HOLD; a target price of $216.000000; an Industry Subrating of High; a Management Subrating of Medium; a Safety Subrating of Medium; a Financial Strength Subrating of Low; a Growth Subrating of Medium; and a Value Subrating of High.

RESMED INC has an Investment Rating of HOLD; a target price of $254.000000; an Industry Subrating of High; a Management Subrating of Medium; a Safety Subrating of Medium; a Financial Strength Subrating of Medium; a Growth Subrating of High; and a Value Subrating of Medium.